
    
      This study will consist of three study periods as follows:

        1. Screening Period of up to 6 weeks (8 weeks if on Mircera)

        2. Treatment Period: a minimum of 52 weeks, a maximum of up to 3 years.

        3. A Follow-up period of 4 weeks.

      A total of up to 820 patients will be randomized in a 1:1 ratio to receive either roxadustat
      or Epoetin alfa (Active Control) in an open-label manner.

      Under Amendment 1, approximately 150 incident dialysis subjects will be randomized to either
      roxadustat or epoetin alfa (active control) in a 1:1 ratio
    
  